ALNY

#340
Alnylam Pharmaceuticals, Inc.
340.41 USD
+2.23%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
335.16
340.48
Rango anual
225.84
495.55
Cambio diario
+2.23%
Variación mensual
+9.38%
Variación en los últimos 6 meses
-27.45%
Cambio anual
+41.92%
Cierres anteriores
333.00
Abrir
335.23
Bid
Ask
Mínimo
335.16
High
340.48
Volumen
556
Ver el calendario completo

Financials

Visión general Informes Estadísticas
Trimestre Año
  • Market Capitalization 45.15 B
  • Employee 2 500
  • Founded 2002
  • CEO Yvonne Greenstreet
  • Website www.alnylam.com
  • Headquarter Massachusetts, United States
  • FIGI BBG000BFGNJ5
  • Industry Technology
Ingresos totales
Beneficio neto
Beneficio básico por acción
Deuda total
Flujo de caja libre
Efectivo y equivalentes
Ratio precio/beneficio
170.67
Relación precio/flujo de caja
14.42

Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

Noticias